US FDA Opens Door For J&J's Spravato To Another MDD Population

 
• By Jessica Merrill

The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression. 

depressed Women sitting head in hands on the bed in the dark bedroom with low light environment, dramatic concept
J&J's Spravato is approved for a new depression indication • Source: Shutterstock

More from Neurological

More from Therapy Areas